| Literature DB >> 32827587 |
Jamie J Coleman1, Adam Botkai2, Ella J Marson2, Felicity Evison3, Jolene Atia3, Jingyi Wang3, Suzy Gallier3, John Speakman3, Tanya Pankhurst3.
Abstract
BACKGROUND: The COVID-19 pandemic has introduced further challenges into Do Not Attempt Cardiopulmonary Resuscitation (DNACPR) decisions. Existing evidence suggests success rates for CPR in COVID-19 patients is low and the risk to healthcare professionals from this aerosol-generating procedure complicates the benefit/harm balance of CPR.Entities:
Keywords: Advance directives; COVID-19; Electronic health records; Resuscitation orders
Mesh:
Year: 2020 PMID: 32827587 PMCID: PMC7438269 DOI: 10.1016/j.resuscitation.2020.08.006
Source DB: PubMed Journal: Resuscitation ISSN: 0300-9572 Impact factor: 5.262
Fig. 1Screenshot of DNACPR/TEAL form in EHR.
Fig. 2(a) Patterns of form completion before and during the COCID-19 pandemic. (b) Close-up view of COVID-19 period compared to March–April 2019.
Demographics of patients with a completed form.
| Pre-COVID | Mar–Apr 2019 | During COVID | p Value | ||
|---|---|---|---|---|---|
| n | 14,163 | 729 | 1844 | ||
| Median patient age (IQR) | 79 (67−87) | 79 (68−87) | 74 (61−83) | <0.001 | |
| Age group (years) | Under 66 | 3199 (22.6%) | 160 (21.9%) | 595 (32.3%) | <0.001 |
| 66−77 | 3207 (22.6%) | 180 (24.7%) | 497 (27.0%) | ||
| 78−84 | 2810 (19.8%) | 142 (19.5%) | 345 (18.7%) | ||
| 85−90 | 2809 (19.8%) | 142 (19.5%) | 272 (14.8%) | ||
| Over 90 | 2138 (15.1%) | 105 (14.4%) | 135 (7.3%) | ||
| Sex | Female | 7373 (52.1%) | 366 (50.2%) | 865 (46.9%) | 0.143 |
| Male | 6790 (47.9%) | 363 (49.8%) | 979 (53.1%) | ||
| Co-morbidities | Cancer | 3502 (24.7%) | 203 (27.8%) | 214 (13.1%) | <0.001 |
| Renal disease | 2759 (19.5%) | 135 (18.5%) | 316 (17.1%) | 0.439 | |
| Congestive Cardiac Failure | 2694 (19.0%) | 119 (16.3%) | 189 (10.3%) | <0.001 | |
| Liver Failure | 362 (2.6 %) | 17 (2.3 %) | 15 (0.8 %) | 0.003 | |
| Palliative Care | 3816 (26.9%) | 208 (28.5%) | 308 (16.7%) | <0.001 | |
| Critical Care | 502 (3.5%) | 19 (2.6%) | 62 (3.4%) | 0.387 | |
| SEWS | SEWS 0 | 4847 (34.2%) | 255 (35.4%) | 549 (29.8%) | 0.012 |
| Low SEWS | 7056 (49.8%) | 334 (45.8%) | 959 (52.0%) | ||
| Medium SEWS | 1287 (9.1%) | 79 (10.8%) | 196 (10.6%) | ||
| High SEWS | 625 (4.4%) | 53 (7.3%) | 103 (5.6%) | ||
| Missing SEWS Information | 348 (2.5%) | 8 (1.1%) | 37 (2.0%) | ||
| Median Length of Stay (IQR) (Days) | 14 (6−27) | 14(6−28) | 6 (3−13) | <0.001 | |
| Patient status at discharge | Alive | 9627 (68.0%) | 505 (69.5%) | 1290 (77.3%) | <0.001 |
| Deceased | 4531 (32.0%) | 222 (30.5%) | 378 (22.7%) | ||
This is only given for the patients who have been discharged when the study was completed.
SEWS — Standardised Early Warning Scoring system.
This P value compares the COVID period to those forms completed in March and April 2019.
Responses on the DNACPR/TEAL form on the PICS EHR.
| Pre-COVID | Mar–Apr 2019 | During COVID | p Value | ||
|---|---|---|---|---|---|
| Completion (total N) | 14,163 | 729 | 1844 | ||
| Doctor would be surprised if patient died on this admission | 2183 (15.4%) | 124 (17.0%) | 575 (31.2%) | <0.001 | |
| DNACPR is in place | 12,650 (89.3%) | 663 (90.9%) | 1406 (76.3%) | <0.001 | |
| Patient is for full active treatment | 3864 (27.3%) | 190 (26.1%) | 563 (30.5%) | 0.028 | |
| Reason not for full active treatment | Patient’s wishes known | 2079 (20.2%) | 105(19.5%) | 242 (18.9%) | 0.107 |
| Futility | 9174 (89.1%) | 469(87.0%) | 1143 (89.2%) | 0.076 | |
| ADRT | 329 (3.2%) | 23(4.3%) | 22 (1.7%) | 0.711 | |
| Patient has capacity to be involved | 5729 (44.6%) | 296 (43.9%) | 839 (58.5%) | <0.001 | |
| Decision was discussed with patient | 5300 (92.5%) | 283 (95.6%) | 804 (95.8%) | 0.871 | |
| Decision was discussed with relatives | 8520 (70.3%) | 480 (75.4%) | 648 (50.6%) | <0.001 | |
| Review date¹ | 7 days: 43.6% | 7 days: 42.4% | 7 days: 42.4% | 0.133 | |
| 28 days: 20.2% | 28 days: 19.7% | 28 days: 23.1% | |||
| Indefinite: 36.4% | Indefinite: 37.9% | Indefinite: 34.4% | |||
This is only completed when the patient is either not for full active treatment or not for active CPR (n = 15,826).
This question is only answered when it is confirmed that the patient has the mental capacity to be involved in decisions (n = 6568).
This is only completed when the patient has either given consent for their conditions to be discussed with relatives or does not have the mental capacity to be involved in decisions (n = 13,405).
Only for those who are not for full active treatment and multiple options can be chosen per patient.
This P value compares the COVID period to those forms completed in March and April 2019.
Age and comorbidities of patients before and during COVID-19 and whether they had a DNACPR put in place or not.
| Pre-COVID | Mar–Apr 2019 | During COVID | p Value | ||
|---|---|---|---|---|---|
| DNACPR is in place | 12,650 (89.3%) | 663 (90.9%) | 1406 (76.3%) | <0.001 | |
| Patients with DNACPR in place | Median patient age (IQR) | 81 (70−88) | 79 (69−87.3) | 74.5 (63.3−82) | 0.015 |
| Cancer | 3215 (25.4%) | 191 (28.8%) | 212 (15.1%) | <0.001 | |
| Renal disease | 2630 (20.8%) | 132 (19.9%) | 286 (20.3%) | 0.819 | |
| Congestive Cardiac Failure | 2543 (20.1%) | 116 (17.5%) | 175 (12.4%) | 0.002 | |
| Liver Failure | 340 (2.7%) | 17 (2.6%) | 12 (0.9%) | 0.003 | |
| Patients without DNACPR in place | Median patient age (IQR) | 58 (43−70) | 61.5 (45−75) | 54.5 (44−65) | 0.006 |
| Cancer | 287 (19.0%) | 12 (18.2%) | 29 (6.6%) | 0.006 | |
| Renal disease | 129 (1.0%) | 3 (0.5%) | 30 (2.1%) | 0.349 | |
| Congestive Cardiac Failure | 151 (1.2%) | 3 (0.5%) | 14 (1.0%) | 0.389 | |
| Liver Failure | 22 (0.2%) | 0 (0.0%) | 3 (0.2%) | 0.656 | |
This P value compares the COVID period to those forms completed in March and April 2019.
Fig. 3Patient preferences on treatment priorities.